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“Recent discoveries in the human genomics of hepatitis C virus 
infection open new avenues in basic science and substantially 
improve our understanding of the natural history of the disease 
and of treatment outcomes.”
Experienced physicians have always used 
personalized therapy in clinical routine, 
long before the term personalized medicine 
was introduced. Optimal patient care is 
based on careful selection of patients who 
need treatment, and of therapeutic regimens 
that are likely to be effective and well toler-
ated. The clinical management of patients 
suffering from chronic hepatitis C virus 
(HCV) infection represents an ideal setting 
to demonstrate the relevance of personalized 
medicine, the intricate roles of genetic and 
nongenetic factors, as well as the opportu-
nities and risks associated with individu-
alization of patient care. In the context of 
chronic HCV infection, the key questions 
are: ‘Who needs therapy?’, ‘Will therapy be 
effective?’ and ‘Will therapy be tolerated?’
Who needs therapy?
The progression of liver disease caused by 
chronic HCV infection is extremely vari-
able. Some individuals will never develop 
clinical disease, while others will die from 
liver-related complications within a few 
years if left untreated. Risk factors that 
have been consistently associated with 
faster progression of liver disease include 
older age at infection, male gender, alcohol 
intake and co-infection with HIV or hep-
atitis B virus [1]. However, none of these 
factors are sufficient to replace a careful 
assessment of liver disease by either liver 
biopsy or noninvasive measurement of 
liver disease. Accordingly, international 
guidelines uniformly recommend an 
assessment of liver disease prior to starting 
HCV therapy. Estimation of the current 
stage of liver disease by histological ana-
lysis of biopsy material or by noninvasive 
markers of liver fibrosis is clearly more 
important for counseling patients than 
demographic, clinical or genetic predic-
tors of fibrosis. However, it remains to be 
established whether the addition of these 
predictors could help further improve 
patient care. For example, individuals 
with moderate fibrosis could be managed 
according to their individual risk assess-
ment, with more urgent treatment or 
closer follow-up proposed to patients with 
high-risk profiles. Currently, even if some 
risk factors are already taken into account 
by treating physicians and occasionally 
‘tip the balance’ for or against therapy in 
difficult cases, the response to the ques-
tion ‘Who needs therapy?’ still largely 
depends on the assessment of liver fibrosis.
“The clinical management of 
patients suffering from chronic 
hepatitis C virus infection 
represents an ideal setting to 
demonstrate the relevance of 
personalized medicine...”
Will therapy be effective?
It has long been known that viral and host 
factors strongly influence the response to 
HCV treatment. Until recently, the viral 
genotype was the strongest predictor of 
response to HCV therapy with pegylated 
interferon and ribavirin (peg-IFN/RBV). 
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Permanent viral eradication can be achieved in up to 80% of 
individuals infected with ‘favorable’ HCV genotypes (2 or 3), 
but only in approximately 40% of those infected with ‘unfavor-
able’ HCV genotypes (1 or 4) [2]. In addition, response rates 
are higher in females, in those with lower HCV RNA levels, 
and in Asians and Caucasians, compared with individuals of 
recent African ancestry [2]. The contribution of human genetic 
variation to treatment response, although suspected, could not be 
convincingly demonstrated before last year, when several genome-
wide association studies reported a major breakthrough in HCV 
genomics. These studies identified variation in the IL28B gene 
region as a major determinant of HCV treatment response [3–7]. 
Shortly thereafter, the same genetic factor was also shown to be 
the strongest predictor of natural HCV clearance [6,8]. In HCV 
genotype 1 infection, IL28B polymorphism was the strongest 
predictor of treatment response, independent of other known 
factors, and also predicted viral kinetics during HCV therapy [9]. 
IL28B encodes IFN-l3 (type III IFN), a cytokine with antiviral 
activity. Additional studies demonstrated that protective IL28B 
genotypes associate with lower pretreatment levels of interferon-
stimulated genes [10], a finding in line with previous observations 
that baseline up regulation of interferon-stimulated genes impairs 
the response to HCV therapy [11]. The association of IL28B vari-
ants with response to HCV therapy was replicated in numerous 
studies, was consistent between ethnicities, and was independent 
of co-infection with HIV (reviewed in [7]). Interestingly, in trans-
planted individuals, both donor and recipient IL28B genotypes 
were associated with response to HCV therapy [12]. While there 
is overwhelming evidence for the role of IL28B variation in the 
host response to HCV genotype 1 or 4 infection, it is uncer-
tain whether IL28B variation has a major impact on treatment 
response in those infected with ‘easy-to-treat’ genotypes (HCV 
genotypes 2 or 3) [6]. 
Predicting treatment efficacy is a difficult task in routine clini-
cal practice. Multiple clinical and laboratory parameters need 
to be considered before and during HCV therapy. The addition 
of IL28B genotypic information can substantially improve the 
prediction of treatment outcomes and can, in some instances, 
help patients and physicians to make more informed decisions 
regarding HCV therapy [13]. For example, genotypic information 
can identify individuals with very low probability of treatment 
response, and thereby avoid potentially harmful side effects of 
an ineffective treatment. IL28B genotypic information can also 
predict HCV eradication during treatment, which can help to 
estimate whether continuing therapy outweighs the risk of side 
effects [9]. 
The role of IL28B genotyping in the coming era of combination 
therapy, associating pegIFN/RBV and protease or polymerase 
inhibitors, has yet to be fully determined. However, as long as 
IFN is included in the treatment regimen, IL28B variation can 
be expected to have a detectable impact, unless the success rate 
approaches 100%. This has recently been demonstrated in a 
cohort of Japanese patients treated with peg-IFN/RBV and the 
protease inhibitor telaprevir, in which IL28B genotype was highly 
associated with treatment response [14]. 
Finally, IL28B genotyping certainly has a place as a random-
ization criterion in early-stage clinical trials of anti-HCV com-
binations that include peg-IFN: any imbalance in the distribu-
tion of IL28B genotypes between study arms would substantially 
confound the results of small-scale trials [15].
Will therapy be tolerated?
Tolerability is a major issue during therapy with peg-IFN/RBV. 
In routine clinical settings, a substantial proportion of individuals 
do not start HCV treatment owing to fear of adverse events [16]. In 
addition, up to 25% of treated individuals stop therapy early owing 
to side effects [17]. In many cases, peg-IFN and/or RBV doses need 
to be reduced, which reduces sustained virological response rates. 
Patients are routinely screened for comorbidities that could repre-
sent contraindications to HCV treatment, but there is otherwise no 
direct way to predict the occurrence of any severe toxicity. Recently, 
a genome-wide association approach was successfully used in the 
search for determinants of drug-induced anemia, which occurs 
in most treated patients and is essentially attributable to RBV-
associated red blood cell destruction: genetic variants associated 
with differences in susceptibility to anemia were identified in the 
inosine triphosphatase (ITPA) gene region [18,19]. Interestingly, 
the association signal was entirely explained by two functional 
polymorphisms that cause ITPA deficiency, a benign enzymopathy 
that turns out to play a significant protective role in the particular 
context of HCV treatment. This finding has the potential to shed 
new light on RBV metabolism and mode of action. 
“The addition of IL28B genotypic information can 
substantially improve the prediction of treatment 
outcomes and can in some instances help patients 
and physicians to make more informed decisions 
regarding hepatitis C virus therapy.”
Genotyping of the ITPA variants allows the identification of a 
minority of patients who are highly unlikely to suffer from severe 
anemia during peg-IFN/RBV therapy. Given the necessary close 
follow-up of blood cell counts during treatment, this information 
will not be very relevant in standard clinical care, but could still 
be helpful in selected cases: for example, a treatment could pos-
sibly be started in a patient with serious cardioischemic or renal 
comorbidity if he has a protective ITPA genotype.
Chances & pitfalls of personalized HCV therapy 
The recent discoveries in the human genomics of HCV infection 
open new avenues in basic science and substantially improve our 
understanding of the natural history of the disease and of treat-
ment outcomes. We can now better predict who will respond to 
HCV therapy and who will tolerate it. However, new knowledge 
brings new challenges to address, and pitfalls to avoid. First and 
foremost, it is essential to explain the nature and the relevance 
of the genetic findings to healthcare providers and patients: the 
genetic variants have strong effects at the population level, but are 
imperfect predictors at the individual level. Genotypes can be used 




assessment. It is also very important to avoid inappropriate denial 
of HCV therapy to individuals who would have responded to treat-
ment despite carrying IL28B risk alleles: health insurers and policy 
makers must understand the imperfect nature of the individual 
genetic prediction. Finally, there are still many open questions, and 
ongoing studies will hopefully help us get a better sense of the true 
relevance of IL28B variation with regards to basic pathogenesis, 
non-1 HCV genotypes and novel combination therapies. 
Hepatitis C just entered the pharmacogenomic era, and it is 
our strong belief that the discoveries discussed here create more 
opportunities than pitfalls. Experienced physicians are used to cau-
tiously interpreting new research findings and will appropriately 
integrate new information into their treatment algorithms. This 
will improve treatment efficacy and tolerability – the ultimate goal 
of personalized hepatitis C therapy.
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